UNLIMITED TURBO SHORT - NOVO-NORDISK B | Market Closed - Euronext Paris 12:30:01 2024-05-24 EDT | ||
| 1.77 EUR | +4.12% |
|
| Current month | -21.03% | ||
| 1 month | -27.56% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-05-24 | 1.84 | +8.24% |
| 24-05-23 | 1.7 | -12.37% |
| 24-05-22 | 1.94 | +2.65% |
| 24-05-21 | 1.89 | -14.48% |
| 24-05-17 | 2.21 | +6.76% |
Real-time Euronext Paris
Last update May 24, 2024 at 12:30 pm
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| 4P7MB | |
| ISIN | NLBNPNL2N591 |
| Date issued | 2024-02-02 |
| Strike | 1,049 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.51 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.035 € |
|---|---|
| Lowest since issue | 1.7 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
928.8
DKK
Average target price
909.2
DKK
Spread / Average Target
-2.11%
- Stock Market
- Certificates
- 4P7MB Certificat
